Literature DB >> 28365056

Idiopathic pulmonary fibrosis.

Luca Richeldi1, Harold R Collard2, Mark G Jones3.   

Abstract

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28365056     DOI: 10.1016/S0140-6736(17)30866-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  335 in total

1.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

2.  Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis.

Authors:  Franco Conforti; Robert Ridley; Christopher Brereton; Aiman Alzetani; Benjamin Johnson; Ben G Marshall; Sophie V Fletcher; Christian H Ottensmeier; Luca Richeldi; Paul Skipp; Yihua Wang; Mark G Jones; Donna E Davies
Journal:  Cell Death Discov       Date:  2020-06-30

Review 3.  Role and mechanisms of autophagy in lung metabolism and repair.

Authors:  Xue Li; Fuxiaonan Zhao; An Wang; Peiyong Cheng; Huaiyong Chen
Journal:  Cell Mol Life Sci       Date:  2021-04-17       Impact factor: 9.261

4.  Licence to kill senescent cells in idiopathic pulmonary fibrosis?

Authors:  Arnaud A Mailleux; Bruno Crestani
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

5.  Thyroid hormone: a resurgent treatment for an emergent concern.

Authors:  Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

6.  Chromatin Landscapes of Human Lung Cells Predict Potentially Functional Chronic Obstructive Pulmonary Disease Genome-Wide Association Study Variants.

Authors:  Christopher J Benway; Jiangyuan Liu; Feng Guo; Fei Du; Scott H Randell; Michael H Cho; Edwin K Silverman; Xiaobo Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2021-07       Impact factor: 6.914

7.  Lung Iron Overload Does Not Exacerbate the Fibrotic Response to Bleomycin in a Mouse Model of Pulmonary Fibrosis.

Authors:  Vida Zhang; Elizabeta Nemeth; Airie Kim
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

Review 8.  Insights from human genetic studies of lung and organ fibrosis.

Authors:  Christine Kim Garcia
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

9.  Mechanical Stretch: An Important and Understudied Feature of Acute and Chronic Lung Injury.

Authors:  Leigh M Cagino; Matthew K Hensley; Sean M Fortier; Robert P Dickson
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

Review 10.  Role of Platelet-Derived Transforming Growth Factor-β1 and Reactive Oxygen Species in Radiation-Induced Organ Fibrosis.

Authors:  Jasimuddin Ahamed; Jeffrey Laurence
Journal:  Antioxid Redox Signal       Date:  2017-07-05       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.